Krystal Biotech, Inc. (BIT:1KRYS)

Italy flag Italy · Delayed Price · Currency is EUR
118.75
0.00 (0.00%)
At close: Jul 18, 2025, 5:30 PM CET
Market Cap3.74B
Revenue (ttm)308.51M
Net Income (ttm)114.69M
Shares Outn/a
EPS (ttm)3.84
PE Ratio32.61
Forward PE20.77
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume7
Open118.75
Previous Close118.75
Day's Range118.75 - 118.75
52-Week Range118.75 - 133.25
Betan/a
RSIn/a
Earnings DateAug 4, 2025

About Krystal Biotech

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 cl... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Employees 275
Stock Exchange Borsa Italiana
Ticker Symbol 1KRYS
Full Company Profile

Financial Performance

In 2024, Krystal Biotech's revenue was $290.52 million, an increase of 473.02% compared to the previous year's $50.70 million. Earnings were $89.16 million, an increase of 715.58%.

Financial numbers in USD Financial Statements

News

There is no news available yet.